54.174.225.82
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
FDA Alerts
Hematology
Trending Topics

FDA grants fast track designation for glioblastoma treatment

Posted on February 1, 2021

The U.S. Food and Drug Administration has granted fast track designation for GLR2007 (Gan & Lee Pharmaceuticals Co, Ltd) for the treatment of patients with glioblastoma, according to a press release.

GLR2007 is a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor.

The 1-year, 2-year, and 5 years survival rates for glioblastoma are 39.3%, 16.9%, and 5.5%, respectively, with untreated patients only surviving on average 3 months.

“The poor prognosis and low survival rates for glioblastomas, demonstrate an unmet need for new treatment options,” said Julius Huang, Director of Global Clinical Sciences, Gan & Lee.

Read the full press release here.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-